The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover

Inclusion Criteria: * Subjects must have completed the 48 weeks of the randomised placebo-controlled study phase followed by the 96 weeks open label denosumab 60 mg SC every 3 months phase. (EudraCT number: 2015-003223-53) * Last denosumab injection minimal 3 months or maximum 4 months before baseline * Able and willing to give written informed consent and to comply with the requirements of the study protocol Exclusion Criteria: * Patients with clinically significant hypersensitivity to any of the components of effervescent alendronate. * Patient who is pregnant or planning pregnancy * Female subjects who are breast-feeding. * History of osteonecrosis of the jaw, and/or recent (within 3 months) tooth extraction or other unhealed dental surgery; or planned invasive dental work during the study * Subject has any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures * Hypocalcaemia. * Oesophageal disease, gastritis, duodenitis, ulcers, or with a recent history (within the previous year) of major gastro-intestinal disease such as peptic ulcer, or active gastro-intestinal bleeding, or surgery of the upper gastro-intestinal tract other than pyloroplasty. * Abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia. * Inability to stand or sit upright for at least 30 minutes.